Thursday, June 18, 2015
| 0700 | Registration and Breakfast |
| 0750 | Welcome Drs. Jaime Escallon and Sunil Verma Conference Co-Chairs |
| 0800 | Keynote Address Targeting Breast Cancer: Applying the Lessons of the Past for the New Generation of Drugs Dr. Dennis Slamon |
| Session 1: Radiology/Genetics/Screening Coordinators: Drs. Derek Muradali and Ellen Warner |
|
| 0900 | Beyond BRCA Dr. Jordan Lerner-Ellis |
| 0920 | The OBSP high risk screening program: Results of the first years Dr. Derek Muradali |
| 0940 | New Breast Screening Techniques Dr. Martin Yaffe |
| 1000 | Appropriate and inappropriate use of breast imaging Dr. Pavel Crystal |
| 1020 | Discussion |
| 1040 | Break |
| Session 2: Radiation Oncology Local and Regional Treatment of Breast Cancer Coordinators: Drs. Eileen Rakovitch and Anthony Fyles, Anne Koch |
|
| 1100 | Current perspective of Regional Radiation in breast cancer Dr. Philip Poortmans |
| 1120 | Optimizing the management of regional nodes; surgical perspective Dr. May Lynn Quan |
| 1140 | Oncotype DCIS validation study Dr. Eileen Rakovitch |
| 1200 | Panel Discussion |
| 1215 | Lunch |
| Session 3: Systemic Therapy Coordinator: Drs. Daniel Rayson and Maureen Trudeau |
|
| 1300 | Personalizing Adjuvant Chemotherapy in Breast Cancer: Are we there yet? Dr. Anil Abraham Joy |
| 1330 | Platinums should be considered as Standard of Care for BRCA positive patients undergoing adjuvant (neoadjuvant) chemotherapy Yes – Dr. Andrea Eisen No – Dr. Nadia Califaretti |
| 1400 | Bisphosphonates in the Adjuvant Setting: Should they be Standard of Care? Yes – Dr. Kathleen Pritchard No – Dr. Sonal Gandhi |
| 1430 | Break |
| 1445 | Key Advances in Her2 positive Breast Cancer Dr. Sunil Verma |
| 1500 | Are we ready to establish a new standard of care for premenopausal patient undergoing anti-estrogen Treatment Dr. Hope Rugo |
| 1520 | Triple Negative Breast Cancer: Moving forward from Biology to Treatment Dr. Karen Gelmon |
| 1540 | Panel Discussion |
| 1600 | Biomarkers and Genomics in Breast Cancer: Are we ready to embrace personalized therapy in Breast Cancer? Dr. Philippe Bedard |
| 1620 | Understanding and overcoming resistance to anti-estrogen treatment Dr. Stephen Chia |
Friday, June 19, 2015
| 0700 | Registration and Breakfast | |
| Session 4: Surgery Coordinators: Drs. Jaime Escallon and Wey Leong |
||
| 0800 | The evolution of Pre-op Breast MRI Dr. David McCready |
|
| 0830 | Are we over treating DCIS Dr. Steven Latosinsky |
|
| 0900 | Bilateral Mastectomy often requested by patient; what should be our advice? Dr. Tulin Cil |
|
| 0930 | Predicting Cancer Behaviour Pathology point of view – Dr Martin Chang Surgeon point of view – Dr. Michael Reedijk |
|
| 1030 | Break | |
| 1045 | Selection criteria for Neoadjuvant therapy Dr. David Cescon |
|
| 1115 | Pre-operative and Intra-operative Decision Making in the Neoadjuvant setting Dr. Jean-François Boileau |
|
| 1145 | Sentinel Node Biopsy in the Neoadjuvant setting Yes – Dr. Jean-François Boileau No – Dr. Ralph George |
|
| 1215 | Panel Discussion | |
| 1230 | Lunch | |
| Session 5: Surgery Oncoplastic Principles Coordinators: Drs. Jaime Escallon and Adena Scheer |
||
| 1330 | Principles of Oncoplastic Surgery Dr. Angel Arnaout |
|
| 1400 | How to get started/OPS tool box Dr. Renee Hanrahan |
|
| 1430 | Questions | |
| 1445 | Oncoplastic Surgery Level I Dr. Adena Scheer |
|
| 1515 | Oncoplastic Surgery Level II Dr. Renee Hanrahan |
1545 | Case Presentations |
| 1615 | Questions | |
| 1630 | Evaluation and Adjournment | |